BIOVIE INC. current report, 15 July 2022

Full document

BioVie Inc. Form 8-K Summary

Business Context and Reporting Period

BioVie Inc. (Nasdaq: BIVI) filed this Current Report on Form 8-K on July 15, 2022, to disclose the entry into a Material Definitive Agreement. The Company is a Nevada corporation focused on developing therapeutic products.

Key Financial Metrics and Transaction Details

This filing reports a private placement transaction rather than periodic financial results. Key metrics include:

  • Transaction Value: Approximately $6 million in aggregate purchase price.
  • Securities Issued: 3,636,364 shares of Class A Common Stock (PIPE Shares) and a warrant to purchase 7,272,728 shares (Warrant Shares).
  • Pricing: PIPE Shares sold at $1.65 per share; Warrant exercise price is $1.82 per share with a five-year term.
  • Investor: Acuitas Group Holdings, LLC, a controlling stockholder 100% owned by Chairman Terren Peizer.
  • Use of Proceeds: Working capital purposes.
  • Transaction Fees: 3.0% cash fee to Oppenheimer & Co. Inc. as sole placement agent.

The filing does not provide current revenue, profit, cash flow, margins, debt, or liquidity figures.

Material Changes

The primary material change is the agreement to issue new equity and warrants to a controlling stockholder. Upon closing, the Company will amend its existing Registration Rights Agreement to include the new securities as Registrable Securities.

Outlook, Risks, and Contingencies

  • Closing Date: Expected on or about August 15, 2022, subject to customary closing conditions.
  • Regulatory Status: Securities sold pursuant to Section 4(a)(2) of the Securities Act and Regulation D.
  • Indemnification: The Company agreed to indemnify Acuitas for liabilities related to breaches of representations, warranties, and covenants.

Investor Verification Checklist

  • Verify the actual closing date of the Private Placement (expected August 15, 2022).
  • Confirm the final net proceeds after deducting the 3.0% placement agent fee.
  • Review the amended Registration Rights Agreement to understand the liquidity implications of the new Registrable Securities.
  • Assess the impact of the warrant exercise price ($1.82) relative to the current market price of the Common Stock.